Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07376226

Effects of Whole Fruit on Blood Sugar in People With Type 2 Diabetes

This study will determine the effects of consuming whole fruit on blood sugar control, liver fat, and cardiovascular health in adults with type 2 diabetes who are not treated with insulin.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Harvard T. H. Chan School of Public Health

Boston, Massachusetts, 02115, United States

Location contact

Courtney M Peterson, PhD

PRINCIPAL_INVESTIGATOR

Kathleen Johnson

CONTACT

[email protected]

617-998-6333

About this study

Diabetes is one of the top three drivers of healthcare costs in the U.S., and nearly half of Americans will develop either diabetes or prediabetes in their lifetime. It is therefore critical to find new strategies to treat or reverse diabetes.

One such approach is adopting a healthy diet, which can dramatically improve blood sugar levels in adults with type 2 diabetes and even induce diabetes remission in some patients. Despite this, not much is known about which food groups are most effective at improving blood sugar levels in patients with diabetes.

Although individuals with type 2 diabetes are often advised to reduce carbohydrate intake, current dietary guidelines also recommend consuming fruit and other carbohydrate-rich foods. This has led to confusion among patients and clinicians about whether eating fruit, particularly in larger amounts, is beneficial or harmful for blood sugar and overall health. Whole fruit differs from many other carbohydrate sources in that whole fruit is rich in fiber, vitamins, minerals, and bioactive plant compounds, while being relatively low in energy density.

Most prior research examining the effects of whole fruit in people with type 2 diabetes has been epidemiologic, focused on individual fruits, or combined whole fruit with fruit juice and/or vegetables into a single food category. As a result, it is unknown how whole fruit, as a food category, affects glycemic control and cardiovascular health.

The investigators previously found that a whole-fruit-rich, Mediterranean-style diet improved blood sugar control and blood pressure in patients with type 2 diabetes and even allowed some patients to wean off all anti-hyperglycemic medications. The investigators will conduct a follow-up study to determine the effects of whole fruit alone on glycemic control, liver fat, and cardiovascular risk factors. The study will be a single-arm controlled feeding study to determine the effects of eating a large amount of whole fruit for 17 weeks on glycemic control (Aim 1), liver fat (Aim 2a), and cardiovascular disease risk factors (Aim 2b) in patients with insulin-independent type 2 diabetes. The primary measures of glycemic control will be mean 24-hour glucose levels (as measured by continuous glucose monitoring) and mean 3-hour glucose levels (as measured during a 3-hour oral glucose tolerance test). These assessments will be supplemented by, and interpreted in light of, other glycemic outcomes, which are listed as outcomes #3-9 below.

By providing controlled, high-quality evidence, this study will determine whether whole fruit is good or bad for patients with type 2 diabetes and will improve dietary guidelines for the hundreds of millions of individuals with type 2 diabetes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥18 years
  • Diagnosed with type 2 diabetes
  • HbA1c between 6.5-12.0%
  • Fasting C-peptide level ≥0.5 ng/ml, indicating the patient does not have beta-cell failure, as measured at screening

Exclusion criteria

  • On insulin
  • Evidence of latent autoimmune diabetes (LADA) or maturity-onset diabetes of the young (MODY)
  • Estimated glomerular filtration rate (eGFR) <45 ml/min per 1.73 m²
  • Heart attack in the past 6 months or severe/unstable heart failure
  • On weight loss medication, including GLP-1 receptor agonists (e.g., semaglutide, dulaglutide)
  • Change in the dosage of a chronic medication that may affect study endpoints within the past 3 months
  • Clinically significant laboratory abnormality (e.g., abnormal hemoglobin levels)
  • Significant gastrointestinal disease, major gastrointestinal surgery, or gallstones
  • Significant cardiovascular, renal, cardiac, liver, lung, adrenal, or nervous system disease that might compromise participant safety or data validity
  • Evidence of cancer (other than non-melanoma skin cancer) within the last 5 years
  • Lost or gained more than 5 lbs (or more than 2% of body weight if the patient weighs >250 lbs) of weight in the past 2 months
  • Pregnant, planning to become pregnant in the next 6 months, or breastfeeding
  • Major psychiatric condition that would affect the ability to participate in the study
  • Not able to eat the provided study meals (e.g., food allergies)
  • Behavioral factors or circumstances that may impede adherence to the dietary intervention
  • Not able to undergo the MRI scan (e.g., due to claustrophobia, implanted metal objects, or body girth ≥60 cm)

Treatment and study plan

Whole Fruit

Other

Participants will consume a large amount of whole fruit for 17 weeks. During the first 6.5 weeks, participants will gradually increase the amount of whole fruit they eat by 5% every 5 days. Once they reach 50% of their calories as whole fruit, they will continue to eat 50% fruit for the remaining 10.5 weeks of the study. This is a controlled feeding study, so participants will consume fruit prepared in a metabolic kitchen. The fruit will consist of fresh fruit, dried fruit, and frozen fruit blended into smoothies. To demonstrate compliance, participants will video-record themselves eating the provided fruit. All participants will receive the same dietary intervention. Participants will otherwise continue their usual diet and lifestyle habits.

Primary outcomes

  1. Mean 24-hour Glucose Levels

    Time frame: Change from baseline to week 17

    Average 24-hour interstitial glucose levels (mg/dl), as measured by continuous glucose monitoring (CGM). If needed, data will be adjusted for any changes in antihyperglycemic medication use, using the medication effect score (MES).

  2. Mean 3-hour Glucose Levels

    Time frame: Change from baseline to week 17

    Mean glucose (mg/dl) during a 3-hour oral glucose tolerance test (OGTT)

  3. Mean 3-hour Insulin

    Time frame: Change from baseline to week 17

    Mean insulin (mU/l) during a 3-hour OGTT

  4. Mean 3-hour C-Peptide

    Time frame: Change from baseline to week 17

    Mean C-Peptide (ng/ml) during a 3-hour OGTT

  5. Insulin Sensitivity

    Time frame: Change from baseline to week 17

    Insulin sensitivity (dl/kg/min/μU/ml) during a 3-hour OGTT, as measured by the Oral C-Peptide Minimal Model

  6. Dynamic Beta-Cell Responsivity

    Time frame: Change from baseline to week 17

    Phi_dynamic during a 3-hour OGTT, as measured by the Oral C-Peptide Minimal Model (which is a set of 5 coupled differential equations; see reference under Citations). Phi_dynamic is a measure of beta-cell responsiveness during first-phase insulin secretion. It is a dimensionless index (arbitrary units), where higher values denote greater insulin secretion

  7. Static Beta-Cell Responsivity

    Time frame: Change from baseline to week 17

    Phi_static during a 3-hour OGTT, as measured by the Oral C-Peptide Minimal Model (which is a set of 5 coupled differential equations; see reference under Citations). Phi_static is a measure of beta-cell responsiveness during second-phase insulin secretion. The units of measure are min^-1, and higher values denote greater insulin secretion.

  8. Glycemic Variability

    Time frame: Change from baseline to week 17

    Measures of glucose variability derived from continuous glucose monitoring, including mean amplitude of glycemic excursions and standard deviation (mg/dl).

  9. Time-in-range Metrics from CGM

    Time frame: Change from baseline to week 17

    Standard time-in-range metrics, including time-below-range (TBR), time-in-range (TIR), and time-above-range (TAR), as standardized by the International Consensus on Time in Range. Values will be reported as percentages of the 24-hour day.

Secondary outcomes

  1. Intrahepatic Lipid (Liver Fat)

    Time frame: Change from baseline to week 17

    Percentage as measured using Magnetic Resonance Spectroscopy (MRS) and 3-point M-Dixon Magnetic Resonance Imaging (MRI)

  2. Body Weight

    Time frame: Change from baseline to week 17

    kg

  3. Systolic and Diastolic Blood Pressure

    Time frame: Change from baseline to week 17

    mm Hg

  4. Heart Rate

    Time frame: Change from baseline to week 17

    beats per minute

  5. Lipids

    Time frame: Change from baseline to week 17

    Fasting total cholesterol (mg/dl), LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), and triglycerides (mg/dl).

Study contacts

Contact information is provided by the study sponsor or research team.

Kathleen Johnson Research Project Manager, MPH, RD

CONTACT

[email protected]

617-998-6333

Sponsors and collaborators

Lead sponsor

Harvard School of Public Health (HSPH)

Other

Registry information

Official study title

Effects of Whole Fruit on Glycemic Control, Liver Fat, and Cardiovascular Disease Risk Factors in Adults With Type 2 Diabetes

Acronym: FRUIT2

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jan 29, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.